NCT03510741View on ClinicalTrials.gov

Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 30, 2020

Study Completion Date

March 30, 2021

Conditions

SchizophreniaSchizophreniform DisordersSchizoaffective Disorder

Interventions

DRUG

Sodium Benzoate

Sodium Benzoate will be administered at 1000mg daily

DRUG

N-Acetylcysteine

N-Acetylcysteine 1000 mgs twice daily dose

DRUG

Placebo

Placebo added to TAU

DRUG

Sodium Benzoate Plus N-Acetylcysteine

Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose

Trial Locations (5)

Unknown

Balochistan Institute of Behavioral Science, Quetta

Institute of Psychiatry, Rawalpindi, Rawalpindi

Abbasi Shaheed Hsopital, Karachi

Civil Hospital Karachi, Karachi

Karwan e Hayat, Karachi

All Listed Sponsors

lead

Pakistan Institute of Living and Learning

OTHER

NCT03510741 - Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder. | Biotech Hunter | Biotech Hunter